CARDIO-TTRansform: Eplontersen Fails to Improve Cardiovascular Outcomes When Added to Standard Therapy in ATTR-CM
As reported on Healio, the phase 3 CARDIO-TTRansform study, the largest clinical trial conducted to date in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), found that adding eplontersen to contemporary…